Comparative Pharmacology
Head-to-head clinical analysis: CELESTONE SOLUSPAN versus DEXASPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELESTONE SOLUSPAN versus DEXASPORIN.
CELESTONE SOLUSPAN vs DEXASPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing immune cell activity.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
1-2 mL (6-12 mg/mL betamethasone acetate and betamethasone sodium phosphate) intramuscularly or intralesionally, repeat every 1-4 weeks as needed.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
None Documented
None Documented
Plasma terminal half-life: betamethasone phosphate ~3-5 hours; betamethasone acetate ~6-8 hours. Clinical duration extended due to ester hydrolysis and depot effect (up to 7-14 days for IM injection).
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Renal: ~65% as metabolites and unchanged drug; biliary/fecal: ~20%; remainder via other pathways.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Category C
Category C
Corticosteroid
Corticosteroid/Antibiotic Combination